{
  "paper_id": "PMC9189975",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189975/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Diagnostic distribution of haematological malignancies and precursor conditions classified by ICD-O-3, Haematological Malignancy Research Network, 2004–2016",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/c3a55aa86bfd/dyab275f1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/c3a55aa86bfd/dyab275f1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/c3a55aa86bfd/dyab275f1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/c3a55aa86bfd/dyab275f1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "dyab275-F1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/c3a55aa86bfd/dyab275f1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9189975/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/c3a55aa86bfd/dyab275f1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "National data availability: Haematological Malignancy Research Network patient cohort and comparison cohort",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/235388e13375/dyab275f2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/235388e13375/dyab275f2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/235388e13375/dyab275f2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/235388e13375/dyab275f2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "dyab275-F2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/235388e13375/dyab275f2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9189975/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/235388e13375/dyab275f2.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Annual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/f2ed0e64287b/dyab275f3.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/f2ed0e64287b/dyab275f3.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/f2ed0e64287b/dyab275f3.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/f2ed0e64287b/dyab275f3.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "dyab275-F3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/f2ed0e64287b/dyab275f3.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9189975/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/f2ed0e64287b/dyab275f3.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "Monthly outpatient attendance rates (per 100 persons) in cases and controls, and rate ratios by outpatient specialty with at least two visits (A) in the 3 years before diagnosis and (B) in the 3 years after diagnosis of monoclonal gammopathy of undetermined significance (MGUS)",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/ea23ef2a9505/dyab275f4.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/ea23ef2a9505/dyab275f4.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/ea23ef2a9505/dyab275f4.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/ea23ef2a9505/dyab275f4.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "dyab275-F4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/ea23ef2a9505/dyab275f4.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9189975/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d72/9189975/ea23ef2a9505/dyab275f4.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In this context, it is important to note that the UK’s National Institute for Health and Clinical Care Excellence (NICE) specifies that conditions such as rheumatoid arthritis and Sjögren’s syndrome require specialist clinical input and patients should be managed as outpatients in secondary care.29\nThe utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nAnnual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In this context, it is important to note that the UK’s National Institute for Health and Clinical Care Excellence (NICE) specifies that conditions such as rheumatoid arthritis and Sjögren’s syndrome require specialist clinical input and patients should be managed as outpatients in secondary care.29\nThe utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nAnnual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In this context, it is important to note that the UK’s National Institute for Health and Clinical Care Excellence (NICE) specifies that conditions such as rheumatoid arthritis and Sjögren’s syndrome require specialist clinical input and patients should be managed as outpatients in secondary care.29\nThe utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nAnnual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In this context, it is important to note that the UK’s National Institute for Health and Clinical Care Excellence (NICE) specifies that conditions such as rheumatoid arthritis and Sjögren’s syndrome require specialist clinical input and patients should be managed as outpatients in secondary care.29\nThe utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nAnnual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In this context, it is important to note that the UK’s National Institute for Health and Clinical Care Excellence (NICE) specifies that conditions such as rheumatoid arthritis and Sjögren’s syndrome require specialist clinical input and patients should be managed as outpatients in secondary care.29\nThe utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nAnnual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In this context, it is important to note that the UK’s National Institute for Health and Clinical Care Excellence (NICE) specifies that conditions such as rheumatoid arthritis and Sjögren’s syndrome require specialist clinical input and patients should be managed as outpatients in secondary care.29\nThe utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nAnnual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In this context, it is important to note that the UK’s National Institute for Health and Clinical Care Excellence (NICE) specifies that conditions such as rheumatoid arthritis and Sjögren’s syndrome require specialist clinical input and patients should be managed as outpatients in secondary care.29\nThe utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nAnnual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In this context, it is important to note that the UK’s National Institute for Health and Clinical Care Excellence (NICE) specifies that conditions such as rheumatoid arthritis and Sjögren’s syndrome require specialist clinical input and patients should be managed as outpatients in secondary care.29\nThe utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nAnnual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Providing generalizable information on clinically meaningful cancer subtypes (Figure 1), ∼38 000 patients newly diagnosed in 2004–2019 with a haematological malignancy or related disorder have entered HMRN’s patient cohort, with a further 2500 new diagnoses being added each year.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The time periods covered by the various data sets, which are updated annually by NHS Digital, are shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In this context, it is important to note that the UK’s National Institute for Health and Clinical Care Excellence (NICE) specifies that conditions such as rheumatoid arthritis and Sjögren’s syndrome require specialist clinical input and patients should be managed as outpatients in secondary care.29\nThe utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nAnnual rheumatology outpatient episode rates (95% confidence intervals) in the 10 years before diagnosis of diffuse large B-cell lymphoma (cases) or pseudo-diagnosis (controls): Haematological Malignancy Research Network diagnoses, 2009–2015In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The utility of the comparison cohort to examine the relationship between rheumatological disorders and other morbidities is illustrated in Figure 3, which compares the annual rheumatology outpatient episode rates for male and female patients in the 10 years preceding their diagnosis of diffuse large B-cell lymphoma (DLBCL) to that of their general-population counterparts.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 3 clearly shows that female rates are around twice those of males (amongst DLBCL patients, as well as their comparators), with DLBCL patients being significantly more likely to have a history of rheumatoid disorders.26 Although the difference between males and females is as expected, it is notable that no evidence of effect modification by gender was found.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition to malignancies, HMRN also collects data on premalignancies (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 4 further illustrates the utility of our new comparison cohort data.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Excluding haematology in which, as expected, outpatient attendances increased markedly just before and after MGUS diagnosis, the largest rate ratios (RRs) both before (Figure 4A) and after (Figure 4B) diagnosis were for nephrology [before diagnosis RR = 4.38, 95% confidence interval (CI) 3.99 to 4.81; after diagnosis RR = 14.7, 95% CI 13.5 to 15.9] and rheumatology (before diagnosis RR = 3.38, 95% CI 3.16 to 3.61; after diagnosis RR = 5.45, 95% CI 5.09 to 5.83).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, comparative analyses are currently confined to the information recorded in the sources listed in Figure 2; data from primary care, for example, are currently unavailable in the study region and, because of its pseudonymized nature, comparison cohort linkages to other data sets can only be performed by NHS Digital.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 4,
    "claims_count": 80,
    "images_downloaded": 4,
    "tables_filtered": 64
  }
}